

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2019/2020 influenza season

as of June 30, 2020

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	1 ^a (0.13%)	38 ^b (1.6%)	38 ^b (1.6%)	0	0	46 (100%)	0	0	0	0	0	13 (100%)	0	0	0	0	0
Number of viruses tested	790	2,427	2,427	333	333	46	63	65	65	65	65	13	86	97	97	97	97
Number of viruses reported	4,951						122						664				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

^a Patients without treatment 1

^b Patients without treatment 25